Pro Medicus expands European reach with $10m hospital deal

The ASX 200 stock announced another contract win.

Key points
  • Pro Medicus secured a 5-year, A$10 million Enterprise PACS contract with University Hospital Heidelberg and German Cancer Research Institute, replacing and consolidating three legacy PACS systems to expand its footprint in the German and European hospital markets.
  • The contract provides Pro Medicus with significant exposure in Europe, enabling UKHD and DKFZ to streamline clinical workflows and improve patient care through the advanced capabilities of the Visage 7 platform.
  • Looking forward, Pro Medicus aims to use this partnership to bolster growth in Europe's healthcare imaging market, leveraging its Visage platform to deliver scalable solutions and continue its strong global expansion.

The Pro Medicus Ltd (ASX: PME) share price is in focus after the company announced a new 5-year, A$10 million enterprise contract, expanding its European presence.

A group of people in a corporate setting do a collective high five.

Image source: Getty Images

What did Pro Medicus report?

  • Signed a 5-year, A$10 million Enterprise PACS contract with University Hospital Heidelberg (UKHD) and German Cancer Research Institute (DKFZ)
  • The deal includes associated hospitals Thoraxklinik Heidelberg and KKH Bergstrasse
  • Pro Medicus will replace and consolidate three legacy PACS systems
  • This expands the Visage Imaging platform's footprint in the German and European hospital markets

What else do investors need to know?

University Hospital Heidelberg is one of Germany's largest academic medical centres, offering significant exposure for Pro Medicus in Europe. The new contract includes not only the main hospital but partner research institutions and associated clinics, broadening the company's reach.

Pro Medicus' Visage 7 platform will enable UKHD and DKFZ to streamline clinical workflows, allowing clinicians and researchers fast, unified access to large volumes of imaging data. This move aims to help translate medical discoveries into direct improvements in patient care more rapidly.

What did Pro Medicus management say?

Dr Sam Hupert, CEO of Pro Medicus Limited, said

We are honoured to partner with UKHD and DKFZ, one of Europe's most important medical and cancer research centers. Visage 7 is uniquely positioned to deliver both the diagnostic performance and the research capabilities required by leading academic medical centers. Together, we are shaping the future of enterprise imaging and help empowering clinicians and researchers to deliver better care.

What's next for Pro Medicus?

Pro Medicus aims to leverage this partnership as a springboard for further growth in Europe's healthcare imaging market. Management is focused on delivering scalable, efficient solutions for large research-based hospitals, supporting both clinical care and scientific innovation.

With this latest deal, Pro Medicus continues to strengthen its presence worldwide, capitalising on its innovative Visage platform and longstanding health technology expertise.

Pro Medicus share price snapshot

Pro Medicus shares have soared 66% over the past year, far outpacing the S&P/ASX 200 Index (ASX: XJO) which has risen around 10% over the same period.

View Original Announcement

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

More on ASX Share Market News

A woman weraing a stripy t-shirt winks as she points to the decorative gold crown on her head.
ASX Share Market News

CBA shares back on top of the ASX 200 as BHP dives 13% this week

CBA shares have rallied 9.5% over the past month whilst BHP tumbled 13% this week.

Read more »

a man wearing a hard hat and a high visibility vest stands with his arms crossed in front of heavy equipment at a mine site.
ASX Share Market News

BHP share price drops 13% to seven-month low in just 1 week. Do experts say buy?

Market analysts offer their advice as BHP shares plunge this week.

Read more »

A distressed young woman reads bad news on her smartphone while standing in a modern indoor setting.
Broker Notes

5 ASX 200 shares experts recommend we buy amid the market carnage this week

ASX 200 shares are down 5.2% this week and back in the red for 2026 overall.

Read more »

Comical investor reading documents and surrounded by calculators.
Broker Notes

Buy, hold, sell: Hub24, Reece, Ramsay Healthcare shares

Analysts reveal their ratings on this financial services provider, plumbing supplies company, and private hospital operator.

Read more »

IPO spelt out on a laptop with a red and green bar chart underneath.
IPOs

Anthropic hits the market. Was it enough to distract investors from a bruised AI sector and Nvidia's scandal?

Was the biggest IPO in US history enough to re-energise the AI trade?

Read more »

A man with his back to the camera holds his hands to his head as he looks to a jagged red line trending sharply downward.
Broker Notes

Three of the worst performers in the ASX 200. Brokers think they're ready to bounce back

There could be a lot of value in these poor performers.

Read more »

Business man marking buy on board and underlining it.
Broker Notes

Leading brokers name 3 ASX shares to buy today

Brokers believe that now could be the time to buy these shares.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Broker Notes

2 ASX shares tipped to grow up to 122% in the next 12 months

These companies could be on the cusp of something big.

Read more »